Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Incoming EMA Chief Throws Weight Behind Antimicrobial Resistance Fight

Executive Summary

Antimicrobial resistance, the lack of new antibiotics, and preserving the effectiveness of existing ones are high on the agenda for the soon-to-be new head of the European Medicines Agency, Emer Cooke.

You may also be interested in...



Coronavirus Notebook: Moderna Claims 94.5% Vaccine Efficacy, Janssen Starts Second ENSEMBLE Trial

The European Medicines Agency has begun a rolling review of Moderna’s mRNA vaccine, and its new executive director, Emer Cooke, has taken up her role with a promise to make tackling COVID-19 her “number one priority.” 

‘Unprecedented’ EMA Response To COVID-19 Must Be Sustained

The agility, flexibility and transparency that the European Medicines Agency has adopted during the development and assessment of COVID-19 products will have to continue after treatments and vaccines are on the market, says the soon-to-be new head of the agency, Emer Cooke.

CTIS: EU Industry Welcomes ‘Landmark Moment’ But Says Issues Still Need Addressing

EFPIA acknowledges that while the mandatory use of the EU Clinical Trials Information System from today is a significant milestone, it says the usability and functionality of the system need to be enhanced and there are also issues with the Clinical Trials Regulation that need to be fixed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel